ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0033

Adenosine A2A Receptor Signaling Enhances Expression of an Endogenous p53 Mouse Variant in Bone Marrow Mesenchymal Stem Cells

Benjamin Friedman1 and Bruce Cronstein2, 1NYU Langone, New York, NY, 2NYU School of Medicine, New York, NY

Meeting: ACR Convergence 2022

Keywords: Aging, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Osteoarthritis and Joint Biology – Basic Science Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Our lab has demonstrated the ability of an intra-articular liposomal formulation of an adenosine A2A receptor (A2AR), CGS21680, to regenerate cartilage in multiple rodent OA models. At the cellular level in chondrocytes, we have shown that activation of A2AR enhances chondrocyte homeostasis, increases mitophagy, and reduces chondrocyte senescence. Moreover, we identified an A2AR-mediated increase in an anti-senescent, anti-aging truncated p53 variant D133p53a in human chondrocytes. These anti-senescent effects have been recapitulated in transgenic mice overexpressing D122p53. Interestingly, a 2014 study reported an endogenous N-terminal mouse p53 variant in HeLa cells (2 separate deletions with loss of amino acids 42-89 and in-frame shift of aa 90-120) with no p53 transactivation potential and inability to upregulate p21 expression despite retention of the first p53 transactivation domain. Hence, we first hypothesized that this mouse p53 variant could be present in mesenchymal stem cells (MSCs), which have chondrogenic capabilities in vitro. Secondly, we hypothesized that A2AR ligation in mouse MSCs would increase expression of this variant.

Methods: Bone marrow MSCs were isolated from 12-week-old mice, treated with or without 1µM CGS21680, and RT-qPCR was performed to assess expression of total and variant p53 using variant specific primers. Primary and secondary gene sequence analysis was employed to evaluate the deleted/shifted region for CpG sites and G-quadruplex structures using the Sequence Manipulation Suite and the GQRS Mapper, respectively.

Results: We did identify this variant in mouse bone marrow MSCs. Furthermore, its expression relative to total p53 was significantly increased in the A2AR agonist treated MSCs compared to control (1.6±0.3 vs. 1.0±0.06, p=0.029, n=3). CpG site analysis revealed that the variant corresponded to a reduction in 4 CpG sites and 3 potential G-quadruplex structures if analyzed in the antisense configuration.

Conclusion: To our knowledge, this is the first report of this variant of mouse p53 noted in cell types aside from the initial report noted above. While more work needs to be done in differentiated cells, A2AR agonism seems to enhance formation of this mouse p53 variant has functional similarities to the D133p53a. Importantly, the deleted regions in this variant contain the key senescence residues in the protein. Further, It is possible that DNA modifications such as CpG methylation and/or alteration in G-quadruplex stability may play a role in such findings.


Disclosures: B. Friedman, None; B. Cronstein, Regenosine.

To cite this abstract in AMA style:

Friedman B, Cronstein B. Adenosine A2A Receptor Signaling Enhances Expression of an Endogenous p53 Mouse Variant in Bone Marrow Mesenchymal Stem Cells [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/adenosine-a2a-receptor-signaling-enhances-expression-of-an-endogenous-p53-mouse-variant-in-bone-marrow-mesenchymal-stem-cells/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-a2a-receptor-signaling-enhances-expression-of-an-endogenous-p53-mouse-variant-in-bone-marrow-mesenchymal-stem-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology